ALX-1393
ALX-1393 is a drug that acts as a selective antagonist for the glycine transporter 1 (GlyT1). It has been researched for its potential use in the treatment of schizophrenia and cognitive disorders.
Pharmacology[edit | edit source]
ALX-1393 is a potent and selective GlyT1 antagonist. It inhibits the reuptake of glycine, an amino acid that acts as an inhibitory neurotransmitter in the central nervous system. By blocking the reuptake of glycine, ALX-1393 increases the concentration of glycine in the synaptic cleft, which can enhance the function of NMDA receptors and potentially improve cognitive function.
Clinical significance[edit | edit source]
Research has suggested that GlyT1 antagonists like ALX-1393 may have therapeutic potential in the treatment of schizophrenia and cognitive disorders. These disorders are thought to be associated with hypofunction of NMDA receptors, and increasing the availability of glycine could help to counteract this.
See also[edit | edit source]
References[edit | edit source]
ALX-1393 Resources | ||
---|---|---|
|
|
Translate to: East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD